IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of Massachusetts

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

Massachusetts $ 124,271,278.13
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
3G Biotech, LLC Use of Zinc Chelators to inhibit Biofilm Formation   $ 244,479.24
3W Consulting Co Multiparameter Screening Method and Multicomponent Drug for Cardiovascular Disease $ 240,250.00 $ 4,229.24
4s3 Bioscience, Inc Intravenous Protein Therapy by Myotonic Dystrophy Type 1 $ 189,538.00 $ 54,941.24
Acceleron Pharma, Inc ACE-031 $ 244,479.24  
Acceleron Pharma, Inc. ACE-536 $ 244,479.25  
Acceleron Pharma, Inc. ACE-435 $ 244,479.24  
Acceleron Pharma, Inc. ACE-011 Anemia $ 244,479.24  
Acceleron Pharma, Inc. ACE-041 $ 244,479.24  
Acetylon Pharmaceuticals Inc Development of novel cancer drug candidate ACY-1215 $ 244,479.25  
ACETYLON PHARMACEUTICALS, INC. ACY-257 A NOVEL HDAC6 INHIBITOR DRUG CANDIDATE FOR INFLAMMATORY DISEASES $ 152,965.50 $ 91,513.75
Aciex Therapeutics, Inc AC-100 Treatmenty for Signs and Symptoms of Dry Eye Syndrome $ 244,479.24  
Aciex Therapeutics, Inc. AC-120 TREATMENT FOR CHRONIC EYELID EDEMA $ 244,479.24  
Aciex Therapeutics, Inc. AC-200- Treatment for Meibomian Gland Disease $ 244,479.24  
ACIEX THERAPEUTICS, INC. AC-150- TREATMENT FOR COMPREHENSIVE ALLERGIC CONJUNCTIVITIS $ 244,479.24  
Acton Pharmaceuticals, Inc. Aerospan (flunisolide hfa 80 mcg) Inhalation Aerosol $ 244,479.25  
Acusphere, Inc AI-700- (perflubutane polymer microspheres) for Injectable Suspension $ 244,479.25  
AdvanDx Inc. PNA FISH $ 244,479.24  
Advantagene Inc Development of PancAtak for Panceatic Cancer $ 20,290.00 $ 124,128.00
Advantagene, Inc. Development of GliAtak for malignant brain tumors $ 244,479.25  
Advantagene, Inc. Development of ProstAtak™ for Prostate Cancer $ 101,602.00 $ 142,877.25
AesRX, LLC AES-103: A new targeted treatment of Sickle Cell Disease $ 173,806.92 $ 70,672.33
Agios Pharmaceuticals Developing novel cancer therapies targeting the key metabolic enzyme PKM2 $ 244,479.25  
Agios Pharmaceuticals Developing novel targeted therapies for gliomas & AML harboring IDH2 & IDH2 mutations $ 244,479.25  
Aileron Therapeutics, Inc BIM Mimetic for Oncology $ 244,479.24  
Aileron Therapeutics, Inc. Stapled Peptide Therapeutic Pipeline $ 244,479.24  
Alfama, Inc. Development of a novel drug to treat acetaminophen-induced acute liver failure (ALF) $ 244,479.24  
Alfama, Inc. Synthesis of improved CORMs to treat acute liver failure and post-operative ileus $ 244,479.24  
Alfama, Inc. Development of a novel drug to prevent to treat post-operative ileus (POI). $ 63,658.34 $ 47,794.70
Alkeus Pharmaceuticals Inc Assessment of ALK001 for the prevention of vision loss in dry macular degeneration $ 129,437.00 $ 115,042.25
Allegro Diagnostics Product Development for BronchoGen (AEGIS Trial) $ 244,479.25  
Alnylam Pharmaceuticals Inc Single Strand RNAi Technology Platform $ 244,479.24  
Alnylam Pharmaceuticals Inc Alnylam Biotherapeutics $ 244,479.24  
Alnylam Pharmaceuticals Inc. ALN-VSP for Liver Cancer $ 244,479.24  
Alnylam Pharmaceuticals, Inc RNAi Therapeutic Delivery Platform $ 244,479.24  
Alnylam Pharmaceuticals, Inc ALN-HTT for Huntington's Disease $ 244,479.24  
Alnylam Pharmaceuticals, Inc ALN-PCS for the treatment of Hypercholesterolemia $ 244,479.24  
Alnylam Pharmaceuticals, Inc. ALN-RSV for Respiratory Syncytial Virus (RSV) infection $ 244,479.24  
Alnylam Pharmaceuticals, Inc. ALN-TTR for the Treatment of Transthyrein-mediated Amyloidosis (ATTR) $ 244,479.24  
Alzcor Pharmaceuticals Inc Modulators of Amyloid Precursor protein(APP)Processing   $ 2,000.00
AmberGen, Inc. Development of Diagnostic and Prognostic Cancer Assays For Personalized Medicine $ 244,479.25  
AmelioMed, LLC Minimally Invasive Targeted Therapeutic Hypothermia for the Treatment of Spinal Cord Injury   $ 4,755.93
Anchor Therapeutics, Inc. Novel long-lived peptide allosteric G protein coupled receptor modulators $ 244,479.25  
Ancora Pharmaceuticals Inc Synthetic Carbohydrate-Based Staphylococcal Vaccine Program $ 244,479.25  
Ancora Pharmaceuticals, Inc Synthetic Carbohydrate-Based Malaria Vaccine Program $ 220,853.50 $ 23,625.75
Anexon Inc ANX-042 treatment of acute decompensated haert failure (ADHF) $ 244,479.25  
Antigen Express Inc Ii-Key Her-2/neu Peptide Vaccine, AE37, for the treatment of breast cancer. $ 244,479.25  
Antigen Express, Inc li-Key Her-2/neu Peptide Vaccine, AE37, for the treatment of prostate cancer $ 244,479.25  
Antigenics Inc. AG-707, Inveestigational therapeutic vaccine for treatment of genital herpes $ 59,891.00 $ 120,350.00
Antigenics Inc.(a Massachusetts corporation) QS-21, Vaccine adjuvant under development to treat infections, cancers, and Alzheimers $ 244,479.25  
Antisoma Inc Amonafide: evading drug resistance in leukemia $ 244,479.24  
Aphios Corporation Development of Zindol, a Novel Anti-Nausea Drug $ 80,968.50 $ 106,759.00
Aphios Corporation Phospholipid Nanosomes Drug Delivery $ 82,652.50 $ 51,873.50
Aphios Corporation Pathogen Inactivation of Human Plasma $ 83,801.00 $ 160,678.25
AQUILUS PHARMACEUTICALS INC Development of AQU-010 for Neuropathic Pain $ 5,460.00 $ 11,714.50
Archemix Corp Hemophilia-ARC19499 $ 244,479.25  
ARIAD PHARMACEUTICALS, INC mTOR Inhibitor-Ridaforolimus $ 244,479.24  
ARIAD PHARMACEUTICALS, INC ALK Inhibitor-AP26113 $ 244,479.24  
ARIAD PHARMACEUTICALS, INC Pan BCR-ABL Inhibitor- AP24534 $ 244,479.24  
ARIETIS CORPORATION Antifungal therapies for the treatment of recalcitrant and recurrent Candida albicans infection $ 76,354.91 $ 168,124.34
Arisaph Pharmaceuticals Inc Niacin Mimetics $ 244,479.25  
Arisaph Pharmaceuticals Inc APO A1 Mimetics $ 102,759.50 $ 132,924.00
Arisaph Pharmaceuticals Inc GLP-1 $ 120,236.00 $ 117,636.00
Arisaph Pharmaceuticals Inc. Endothelial Lipase Inhibitors $ 148,986.00 $ 95,493.25
Arisaph Pharmaceuticals, Inc Small Molecule Enhancers for Cancer Vaccines $ 179,287.50 $ 65,191.75
Arisaph Pharmaceuticals, Inc Stabilized Peptide Hormones $ 111,473.50 $ 67,985.50
Arisaph Pharmaceuticals, Inc Tumor-Activated Prodrugs $ 244,479.25  
ARISAPH PHARMACEUTICALS, INC OBESITY/METABOLIC DISORDERS-MULTIMEDIATORS $ 198,579.00 $ 45,900.25
Arisaph Pharmaceuticals, Inc Tumor Diagnotics $ 150,059.50 $ 94,419.75
Arisaph Pharmaceuticals, Inc. DPP-4 Inhibitors $ 244,479.25  
Arisaph Pharmaceuticals, Inc. Kinetically Dosed Tumor Selective Proteosome Inhibitors $ 181,868.50 $ 62,610.75
Arisaph Pharmaceuticals, Inc. Stable NPY Analogs $ 111,046.50 $ 67,610.50
Arqule Inc Inhibitors of Mutant BRAF Kinase in Cancer $ 244,479.24  
Arqule Inc ARQ 621 Cancer Drug Project $ 244,479.24  
Arqule, Inc. ARQ-197 Cencer Drug Development Project $ 244,479.24  
Arqule, Inc. ARQ -087 Fibroblast Growth Factor Receptor (FGFR) inhibitor Project $ 244,479.24  
Arsenal Medical, Inc. Therapeutic Drug Delivery Bioabsorbable Vascular Stent $ 244,479.25  
Artisan Pharma Inc ART-123 $ 244,479.25  
Aspen Medisys LLC Magnetic Hanoportide Thermathempy for treating cancer   $ 244,479.25
Attention Therapeutics, Inc. Development of Attention Therapeutic System for regulatory clearance/commercialization.   $ 173,371.50
Audax Medical, Inc Twin-base linker (TBL) bone augmentation   $ 206,885.00
Augmenix, Inc SpaceOAR $ 244,479.25  
Aura Biosciences Inc Development of a topical self-administered treatment for cervical and anal dysplasia $ 244,479.24  
Aura Medsystems, Inc. Light-activated Soft Tissue Repair (laSTR) $ 206,804.50 $ 37,674.75
Auxocell laboratories, Inc. Co - Transplanation of Wharton's Jellly Stem Cells and Cord Blood Stem Cells $ 244,479.24  
Auxocell Laboratories, Inc. Medical Device to Process Wharton's Jelly Stem Cells $ 200,000.00 $ 44,479.24
Avaxia Biologics, Inc Development of AVX-470 for the treatment of Gastrointestinal Inflammatory Disorders $ 24,168.78 $ 220,310.46
Avedro, Inc. Novel Therapy Using Microwave and Ultraviolet Energy to Treat Degenerative Corneal Disease $ 244,479.25  
AVEO Pharmaceuticals, Inc Tivozanib-A Potent and Selective Triple VEGF-R Inhibitor $ 244,479.25  
AVEO Pharmaceuticals, Inc AV-299- A Novel HGF/c-Met Inhibitor $ 244,479.25  
AVEO Pharmaceuticals, Inc. Human Response Platform™ and Antibody Programs $ 244,479.25  
Avila Therapeutics Inc. Inhibition of Bruton's tyrosine kinase [Btk} to treat blood cancers and autoimmune diseases. $ 244,479.24  
Avila Therapeutics, Inc Development of novel therapies, AVL-181 and AVL-192 to treat Hepatitis C Virus infection $ 244,479.24  
Bach Pharma, Inc a novel neuroprotective agent $ 244,479.24  
BG Medicine Inc The BGM Galectin-3 blood test for predicting development and progression of heart failure $ 244,479.25  
BG Medicine, Inc. AMIPredict™ : A novel molecular diagnostic for near-term heart attack or stroke $ 244,479.25  
Bikam Pharmaceuticals Pharmacotherapeutics for the Treatment of Retinitis Pigmentosa $ 244,479.24  
Bind Biosciences, Inc Development of targeted nanoparticle therapeutics containing highly potent cytonixic agents $ 244,479.24  
BIND Biosciences, Inc Development of BIND-014--a solid tumor-targeted nanoparticle containing docetaxel $ 244,479.24  
BIND Biosciences, Inc Develop a Medicinal Nanoengineering ™ platform for polymer-based targeted nanoparticle $ 244,479.24  
BIO2  Technologies, Inc. Surface Active Tissue Engineering Scaffold $ 18,614.00 $ 225,865.24
BIO2 Technologies, Inc. Resorbable Tissue Engineering Scaffold $ 55,445.50 $ 189,033.74
BioAssets Development Corp Development of a TNF Inhibitor Drug for the Treaments of Sciatica. $ 244,479.24  
BioBehavioral Diagnostics Company Expansion of Use of the Quotient ADHD System $ 230,018.50 $ 14,460.75
BioChemics Inc Transdermal Diabetic Neuropathy Treatment (BC-DN-01) $ 147,004.66 $ 97,474.59
BioNevia Pharmaceuticals Inc Arresting progression of diabetic Neuropathy with Epalrestat (BNV-222) $ 162,689.50 $ 81,789.74
BioScale, Inc ViBe platform and AMMP assay for biomarker measurement in therapeutics and Dx $ 244,479.25  
BioSensics LLC Sensor-based Auto-BioFeedback and Health Monitoring System $ 9,250.00 $ 104,230.00
Bio-Tree Systems, Inc OncoTree discovery $ 244,479.25  
Biousian Biosystems Inc Novel Therapeutics for the treatment of Chronic Pain and Diabetes $ 61,464.50 $ 73,113.00
BioVex, Inc. The OPTiHaN Trial:  A Phase 3 Trial to Evaluate OncoVEX in Head and Neck Cancer $ 2,962.50 $ 241,516.74
BioVex, Inc. The OPTiM Trial: A Randomized Phase 3 Clinical Trial to Evaluate OncoVEX $ 244,479.24  
Birch Tree Medical, Inc. Use of longterm patient-controlled heat to relieve Restless leg Syndrome   $ 206,000.00
Boston Biomedical, Inc BB15600 Anti-Cancer Stem Cell Drug Discovery and Deveopment Program $ 7,673.39 $ 236,805.85
Boston Biomedical, Inc. BBI8000 Anti-Cancer Drug Discovery and Development Program $ 4,024.94 $ 240,454.31
Boston Biomedical, Inc. BB16000 Anti-Cancer Stem Cell Drug Discovery and Development Program $ 244,479.24  
Boston Endoscopic Engineering Corporation Therapeutic Gastrointestinal Delivery Platform for EUS fine needle aspiration $ 185,052.50 $ 59,426.74
Boston Microfluidics Inc Rapid Point-of-Care Test Platform $ 244,479.24  
Braintree Laboratories, Inc BLI801- SULFATE LAXATIVE $ 64,956.50 $ 146,603.50
Braintree Laboratories, Inc. BLI1100-MEDIDERMIS $ 152,698.50 $ 91,780.75
Braintree Laboratories, Inc. PCD03 - METRONIDAZOLE 10% Ointment   $ 244,479.25
Cambrooke Foods, LLC BetterMilk with Glycomacropeptide for Phenylketonuria(PKU) $ 80,095.50  
Cardiorobotics, Inc. Articulated Robotic Medprobe (ARM) Robotic System $ 244,479.25  
Catabasis Pharmaceuticals, Inc Fatty Acid Salicylate Conjugates as Novel Therapeutics for the Treatment of Type 2 Diabetes $ 244,479.24  
Celexion LLC Isolation of Therapeutic Binders to Oncogenic Targets $ 78,118.00 $ 166,361.24
Cellay, Inc. New Method for Cancer Diagnosis $ 244,479.24  
Cellceutix Corporation KM-133 for Treatment of Psoriasis $ 141,984.50 $ 102,494.75
Cellceutix Corporation Kevetrin for Cancer Treatment $ 244,479.25  
Cellceutix Corporation KM-391 For Treatment of Autism $ 142,830.00 $ 101,649.25
Celldex Therapeutics Inc CDX-301 $ 244,479.24  
Celldex Therapeutics Inc CDX-1307 $ 244,479.24  
Celldex Therapeutics Inc CDX-011 $ 244,479.24  
Celldex Therapeutics Inc CDX-1127 $ 244,479.24  
Celldex Therapeutics, Inc. Rindopepimut (CDX-110) $ 244,479.24  
Celldex Therapeutics, Inc. CDX-1135 $ 133,360.50 $ 111,118.74
Celldex Therapeutics, Inc. CDX-1401 $ 244,479.24  
CellThera, Inc. Functional restoration of a large-scale skeletal muscle defect using dedifferentiated cells $ 219,093.50 $ 25,385.74
Celthera, Inc. Regenerative Platform $ 25,716.54 $ 4,803.25
Cephalogics LLC high-Density Diffuse Optical Tomography for Real-Time Neurological Assessment in Infants $ 67,612.00 $ 93,531.70
Cequent Pharmaceuticals, Inc. CEQ508 $ 244,479.25  
Cequent Pharmaceuticals, Inc. CEQ626 $ 244,479.25  
CeQur Corporation CeQur Insulin Delivery Device for Use in Type 2 Diabetes $ 244,479.24  
Cerenova, Inc Neurostimulation for neurotrauma rehabilitation   $ 244,479.25
Cerulean Pharma Inc CRLX101 (formerly IT-101)A Novel Nanopharmaceutical Oncology Agent in Phase 2 $ 244,479.25  
Cerulean Pharma Inc Nanopharmaceutical Docetaxel-A Promising Next Generation Oncology Agent $ 244,479.25  
Cerulean Pharma Inc. Nanopharmaceutical Drug Delivery Patform Enabling RNA Interference Therapy   $ 244,479.25
Claros Diagnostics, Inc. Point-of-Care Diagnostic System for Urologist Office Use $ 244,479.24  
CombinatoRX ,Inc Synavive Project $ 244,479.24  
Combinent Biomedical Systems, Inc. CBMS-10 $ 221,188.93 $ 23,290.31
Concert Medical, LLC Concert Conductor Guidewire   $ 35, 650.50
Concert Medical, LLC Concert N2009 Guidewire   $ 24, 927.00
Concert Pharmaceuticals, Inc Novel HIV protease inhibitor not requiring co-dosing with a pharmacokinetic boosting agent $ 244,479.24  
Concert Pharmaceuticals, Inc Novel Treatment for Diabetic Nephropathy $ 244,479.24  
Constellation Pharmaceuticals, Inc New Therapeutics That Target Epigenetic Regulatory Proteins in Cancer $ 244,479.25  
CorNova Inc The FiberHalo Catheter $ 244,479.25  
Correx Inc Correx 18-mm Aortic Valve Bypass Kit $ 244,479.25  
Creagen Biosciences, Inc Anticancer agents based on a dual function structures $ 205,841.50 $ 38,637.74
Curaxis Pharmaceutical Corporation ALADDIN Clinical Trials   $ 39, 154.00
CuriRx Inc Novel anti-cancer drug candidate $ 15,410.00 $ 109,750.00
Curis Inc Multi-targeted network inhibitor platform for cancer $ 244,479.25  
Curis, Inc CUDC-101, a Phase 1 cancer agent $ 244,479.25  
CYTOCURE LLC Novel Combination Immunotherapy of Cancer:  Drugs that Enhance Tumor Antigens $ 120,224.00 $ 124,255.25
Cytonome/ST, LLC Therapeutic Cell Sorter for Blood Cancers $ 244,479.25  
CytoVera Inc High Potency Cord Blood Stem Cells as Therapeutics for Treatment for Treating Blood Cancers in Adults. $ 7,926.50 $ 125,000.00
Daktari Diagnostics Inc. Development of a Handheld CD4 Cell Counter for Point-of-Care Monitoring of HIV Patients $ 244,479.24  
Dicerna Pharmaceuticals Inc A Novel Castration Restitant Prostate Cancer Treatment Targeting Androgen Receptor $ 244,479.24  
Dicerna Pharmaceuticals Inc Dicer Substrate Technology ™, a new and novel RNAi-based drug development platform $ 244,479.24  
Differential Proteomics, Inc. Antibody Repertoire Profiling for Enabling Detection, Diagnosis and Treatment of Diseases $ 132,836.84 $ 111,642.41
DNA Medicine Institute, Inc. Universal Blood Sensor $ 54,048.50 $ 168,950.00
Dragonfly Sciences, Inc Etanercept Biosimilar $ 244,479.25  
Dune Medical Devices Inc MarginProbe System $ 244,479.25  
Dyax Corp FcRn (DX-2500) $ 220,011.50 $ 24,467.75
Dyax Corp DX-88 HAE KALBITOR $ 244,479.25  
Dyax Corp DX-2400 $ 244,479.25  
Dyax Corp ACE inhibitor Induced Angioedema $ 179,610.00 $ 64,869.25
Dyax Corp. MMP-9 (DX-2802) $ 244,479.25  
Dyax Corp. Plasma Kallikrein Inhibitor $ 244,479.25  
EarthGenes Pharmaceuticals LLC Antibiotic Drug Discovery from Environmental DNA Expression Libraries $ 69,882.50 $ 166,689.50
Echo Therapeutics, Inc Symphony Transdermal Continuous Glucose Monitoring System $ 244,479.25  
ECW Therapeutics, Inc Adults & Neonatal Stem Cell Seperation Device   $ 80,000.00
Edimer Pharmaceuticals EDI200, a recombinant protein for treatment of X-linked hypohidrotic ectodermal dysplasia. $ 244,479.24  
Eleven Biotherapeutics Inc Protein based drug discovery project Myostatin for Muscle wasting   $ 244,479.25
Eleven Biotherapeutics, Inc. Protein-based drug discovery project:  T helper cell, 17 in inflammatory diseases   $ 244,479.25
Eleven Biotherapeutics, Inc. Protein-based drug discovery project: Factor VIII for the treatment of Hemophilla A   $ 244,479.25
Elixir Pharmaceuticals, Inc Development of a Small Molecule Ghrelin Antagonist, EX-1832, for the Treatment of Metabolic Disorders $ 244,479.25  
Enanta Pharmaceuticals Inc Novel Oral Antibiotic for the treatment of MRSA, VRE and Resistant Strep Infections   $ 211,295.50
Enanta Pharmaceuticals Inc Novel NS5A Inhibitors for the treatment of Hepatitis C Infection $ 49,673.00  
Enanta Pharmaceuticals Inc. Novel I.V. Antibiotic for the treatment of MRSA, VRE and resistant Strep Infections   $ 49,673.00
Enanta Pharmaceuticals, Inc Novel Cyclophilin inhibitors for the Treatment of Hepatitis C Infection $ 244,479.24  
Endra Inc Thermoacoustic imaging device for point of care diagnosticapplications $ 129,189.02 $ 115,290.23
Energesis Pharmaceuticals Inc Discovery of Novel Brown Fat Targeting Drugs for Obesity   $ 244,479.24
Enlight Biosciences, LLC Enigma Liver Toxicity $ 41,214.64 $ 79,990.33
Enlight Biosciences, LLC Ensof Biomarker Discovery $ 27,992.37 $ 216,486.88
Enlight Biosciences, LLC Entrega Drug Delivery $ 118,888.34 $ 125,590.91
Ensemble Therapeutics Corporation DNA-Programmed Chemistry and its Application for the Discovery of Novel Oncology Drugs. $ 244,479.24  
Ensemble Therapeutics Corporation New Personalized Medicine Diagnostics for Predicting Drug Resistance in Breast Cancer $ 244,479.24  
Ensemble Therapeutics Corporation Oral Macrocycle Drugs for Treatment of Rheumatiod Arthritis & Other Inflammatory Diseases. $ 244,479.24  
Entra Pharmaceuticals Inc Novel Biopharmaceuticals Drug Delivery System $ 244,479.25  
Epizyme Inc WHSC1 Therapeutic Project   $ 244,479.24
Epizyme Inc DOT1L Therapeutic Project $ 244,479.24  
Epizyme Inc EZH2 Therapeutic Project $ 244,479.24  
ETEX Corporation Bone Regenerating Biomaterial $ 244,479.24  
Euthymics Bioscience, Inc EB-1020: A novel treatment for adult Attention Deficit Hyperactivity Disorder (ADHD) $ 5,802.50 $ 238,676.75
Euthymics Bioscience, Inc. EB-1010: A NOVEL ANTIDEPRESSANT TO PATIENTS NOT RESPONDING ADEQUATELY TO SSRIs $ 52,224.00 $ 192,255.25
Eutropics Pharmaceuticals Developing BH3 profiling as a predictive diagnostic test for multiple myeloma $ 32,910.50 $ 105,652.50
Eutropics Pharmaceuticals Developing Small molecule inhibitor of Mcl-1to treat blood cancer $ 78,719.00 $ 165,760.25
Excelimmune Inc. Development and Manufacture of Human Recombinant Polyclonal Antibodies (HRPA) $ 244,479.24  
Eyegate Pharmaceuticals Inc Biologics $ 56,500.00 $ 173,500.00
EyeGate Pharmaceuticals Inc Nanoparticles $ 174,500.00 $ 69,979.25
Eyegate Pharmaceuticals Inc EGP 437 $ 244,479.25  
Eyegate Pharmaceuticals, Inc EyeGate III $ 244,479.25  
Fifth Base, LLC Prevention of Tumor Recurrence via Flexible Chemotherapy-Eluting Strips $ 55,799.14 $ 22,539.94
First Light Biosciences, Inc Novel low-cost automated platform for rapid and sensative detection of resistant bacteria $ 244,479.25  
Flexion Therapeutics Inc FX005 Intra-articular Injection for Treatment of Pain in Osteoarthritis of the Knee $ 244,479.25  
Flexion Therapeutics, Inc. FX004- Acamprosate for the Treatment of Tinnitus $ 137,784.50 $ 106,694.75
FoldRx Pharmaceuticals Tafamidis for the treatment of TTR Amyloidosis $ 244,479.25  
Forma Therapeutics, Inc Unduggable Targets Important for Cancer Treatment (Protein/Protein Interactions) $ 244,479.25  
Forma Therapeutics, Inc NAMPT $ 244,479.25  
Forma Therapeutics, Inc Diversity-Oriented Synthesis (DOS) Chemistry $ 244,479.25  
Formatech Inc Miradocetaxel Development $ 15,635.50 $ 113,901.50
Foundation Medicine, Inc. Molecular Cancer Diagnostics   $ 244,479.25
Galenea Corp. 5-HT6 Antagonists for cognitive improvement in schizophrenia $ 65,651.00 $ 178,828.25
GALENEA CORP. 5-HT2C Agonists for Appetite Suppression in Obesity $ 244,479.25  
Galenea Corp. Discovery of novel mechanism-based therapies for Schizophrenia $ 244,479.25  
Gelesis Inc Gelesis Novel Hydrogels $ 244,479.25  
Gene Network Sciences, Inc Collaboration with Biogen Idec Phase I   $ 28,457.50
Genetix Pharmaceuticals Inc Lentiglobin $ 244,479.24  
Genetix Pharmaceuticals Inc Lenti-D $ 244,479.24  
Genocea Biosciences, Inc Development of a Chlamydia Vaccine Based on Natural Immunity in Humans $ 244,479.24  
Genocea Biosciences, Inc. Development of Vaccines for Genital Herpes Based on Natural Immunity in Humans $ 244,479.24  
GI Dynamics, Inc. The EndoBarrier for treatment of type 2 diabetes and obesity $ 244,479.25  
GLSynthesis Inc Hybrid Molecules Designed to Enhance Antibiotic Activity $ 244,479.24  
GLSynthesis Inc. Novel drugs to treat Urinary Incontinence $ 244,479.24  
GLSynthesis Inc. Preclinical development of a novel antibacterial for Clostridium difficile disease   $ 219,164.00
GLSynthesis Inc. Novel Antithrombotic Diadenosine Tetraphosphate Analogs $ 151,747.00 $ 92,732.24
GLSynthesis, Inc. Rapid in vitro Substrate Assay for the multi-drug Resistant P-glycoprotein $ 107,992.00 $ 132,649.50
Glycosyn, Inc. Oligosaccharides to Prevent Infectious Diarrhea $ 155,208.00 $ 89,271.24
Good Start Genetics GSG Molecular Genetic Screen Platform $ 145,925.39 $ 98,553.86
Grove Instruments Inc Nonivasive glucose monitor for diabetic patients $ 244,479.25  
Healthrageous, Inc. SmartHealth: Hypertension Self-Management   $ 244,479.25
Helicos BioSciences Corporation Non-invasive detection of genetic disorders for prenatal diagnostics $ 138,671.50 $ 93,884.50
Helicos BioSciences Corporation Identification of disease-specific mutations and polymorphisms in affected individuals $ 244,479.25  
Helicos BioSciences Corporation Detection of pathogen nucleic acid contamination in body fluids & in biological therapeutics $ 88,828.50 $ 155,650.75
Hemedex, Inc. Novel Device to Diagnose Conditions of Compromised Blood Flow and to Quantify Edema $ 244,479.25  
Highland Instruments Electrosonic Stimulation for Noninvasive deep Brain Stimulation $ 47,534.00 $ 68,890.00
Histogenics Corporation NeoCart (Cultured Autologous Neo-Cartilage) $ 244,479.24  
Hybrid Silica Technologies Inc Multimodal Silica Nanoparticles as Cancer Targeted Probes for Clinical Translation $ 228,130.00 $ 16,349.25
Hydra Biosciences, Inc TRPA1 Antagonists as a Broad Medical Countermeasure to Biological and Chemical Threats $ 200,753.50 $ 43,725.74
Hydra Biosciences, Inc. TRPA1 Antagonists as New Treatments for Pain due to injury or inflamation $ 244,479.24  
Hydra Biosciences, Inc. TRPV3 Antagonists as New Treatments for Chronic and Acute Pain $ 244,479.24  
ImmuneXcite, Inc A unique Herceptin conjugate directs neutrophils to fight breast cancer $ 42,352.50 $ 68,737.50
ImmunoDiagnostics, Inc Jak2/Hexim1 kinase inhibitors as therapeutics for the treatment of viral (HIV) disorders $ 107,730.00 $ 136,749.25
ImmunoGen Inc IMGN009- Antibody-drug conjugate to fight cancer $ 244,479.24  
ImmunoGen Inc. IMGN007 Antibody-drug conjugate to fight cancer. $ 153,250.00 $ 91,229.24
ImmunoGen Inc. IMGN529 Antibody-drug conjugate. $ 244,479.24  
ImmunoGen Inc. IMGN388 antibody-drug conjugate $ 244,479.24  
ImmunoGen, Inc. Lorvotuzumab mertansine - IMGN901 - antibody-drug conjugate $ 244,479.24  
Inanovate Inc Development of a low-cost, accurate cancer diagnostic platform. $ 227,192.05 $ 17,287.19
InaVein, LLC Office-based Varicose Vein Treatment with Local Anesthesia   $ 38,494.50
Infinity Discovery, Inc Hsp90 Chaperone Inhibitor Program $ 244,479.24  
Infinity Discovery, Inc IPI 926 Hedgehog Pathway Inhibitor Program $ 244,479.25  
Infinity Discovery, Inc IPI-940 Fatty acid Amide Hydrolase Inhibitor Program $ 244,479.25  
InfraReDx, Inc Clinical validation of near-infrared spectoscopy for diagnosing high risk coronary plaques $ 244,479.25  
InfraReDx, Inc LipiScan ™  IVUS Diagnostic System $ 244,479.25  
InnerSea Technology Inc Early Warning System for Spinal Cord injured at Risk for Autonomic Dysreflexia $ 103,489.50 $ 106,677.00
Inotek Pharmaceuticals Corporation INO-8875 $ 244,479.24  
Inotek Pharmaceuticals Corporation Development of PARPs for use in oncology treatment $ 178,152.67 $ 66,326.58
Inotek Pharmaceuticals Corporation INO-4885 $ 182,507.61 $ 27,493.59
Intact Medical Corp Breast Lesion Excision System $ 244,479.24  
Intelect Medical, Inc. Novel Programming Device to Further the Delivery of Deep Brain Stimulation Devices $ 244,479.25  
Intelligent Bio-Systems DNA Sequence Based Cancer Diagnostic System $ 244,479.25  
Intelligent Medical Devices Inc XMRV and other molecular factors to assess prostate cancer $ 11,214.00 $ 96,384.50
Intelligent Medical Devices Inc Low Cost Screening for Healthcare Associated infections $ 209,418.00 $ 35,061.25
Intelligent Medical Devices Inc Detection and Resistance Screening for Influenza $ 244,479.25  
Intelligent Medical Devices, Inc Monitoring Viruses Associated with Transplant Rejection $ 117,346.50 $ 73,475.50
Intelligent Medical Devices, Inc. Comprehensive Test to Guide Treatment and Prevent Outbreaks of Whooping Cough $ 97,308.50 $ 147,170.75
Interlace Medical, Inc MyoSure Rod Lens Hysteroscope Development Project $ 244,479.25  
Interleukin Genetics Osteoarthritis $ 128,071.00 $ 100,843.50
Interleukin Genetics Inc Perilipin $ 227,377.00 $ 17,102.25
InVivo Therapeutics Corporation Safety and Efficacy of an Implanted Biodegradable Polymeric Scaffold to Treat Spinal Cord injury $ 244,479.25  
IQuum, Inc Rapid Point of Care Molecular Diagnostics for Influenza; Seasonal & Pandemic H1N1 Assays $ 244,479.25  
Iquum, Inc. Rapid, Point of Care Molecular Diagnostic Assay for Detection of Fungemia $ 76,541.00 $ 167,938.25
Ironwood Pharmaceuticals Inc Development of Novel CRTH2 Inhibitor, IW-1221, for Treatment of Asthma   $ 244,479.25
Ironwood Pharmaceuticals Inc FAAH Inhibitor, IW-6118 to Treat Pain and Inflammation $ 244,479.25  
Ironwood Pharmaceuticals, Inc Linaclotide, A Novel Guanylate Cycase C Agonist $ 244,479.25  
Ironwood Pharmaceuticals, Inc. IW-9179, for Treatment of Gastroparesis and Functional Dyspepsia. $ 180,000.00 $ 64,479.25
Ischemix LLC CMX-2043 $ 244,479.24  
Jasco Pharmaceuticals, LLC The Pim Inhibitor Project $ 244,479.24  
JB Therapeutics Inc Clinical Development of an oral, non-psychotropic CB1/CB2 Cannabinoid Agonist for the treat Chronic Pain $ 19,587.50 $ 224,891.75
JEF Core, Incorporated Development of a Lead Based System for Respiratory Variation Monitoring $ 41,392.00 $ 160,749.50
Kala Pharmaceuticals, Inc. Development of KALA617, a once-daily inhalable b-lactam to treat Cystic Fibrosis infections $ 12,500.00 $ 231,979.24
KARYOPHAM THERAPEUTICS NOVEL CRM1 INHIBITORS FOR THE TREATMENT OF CANCER $ 92,500.00 $ 151,979.25
Ligon Discovery Inc Development of HIF inhibitors for Renal Cell Carcinoma $ 244,479.25  
Link Medicine Corporation LNK-3248:  Treating Alzheimer's Disease by Clearing Toxic Proteins $ 63,348.00 $ 181,131.25
Link Medicine Corporation LNK-754 Enhancing Autophagy and Mitochondrial Function to Treat Alzheimer's Disease $ 244,479.25  
Link Medicine Corporation LNK-3186: Developing Novel Treatments for Alzheimer's Disease $ 166,439.00 $ 78,040.25
LOGICAL THERAPEUTICS, INC LT-NS001 (NAXPROXEN ETEMESIL) $ 244,479.25  
Lubris LLC Prevention and Treatment of Osteoarthritis $ 23,550.00  
Marine Polymer Technologies Inc Development of Novel Biomaterial for Trauma Hemorrhage, Diabetic, & Infected Wound Care $ 201,000.50 $ 43,478.75
Marine Polymer Technologies Inc Development of IL-15 Protein Complex as a Therapy for Lymphopenia & Cancer $ 79,633.00 $ 45,878.00
MC10, Inc. Conformal Electronics for Diagnosing and Treating Heart Disease $ 204,079.79 $ 40,399.46
Medical Discovery Partners LLC A Blood Test for the Early Detection of Cancer $ 60,887.00 $ 163,617.50
Medwell Foods, Inc Medwell 1-2-3 Molecular Baking $ 244,479.25  
Mercator Therapeutics, Inc. The Tumor Targeting Project   $ 244,479.25
Mercury Therapeutics, Inc Development of Direct AMP Kinase Activators for Type 2 Diabetes $ 184,696.97 $ 59,782.28
Merrimack Pharmaceuticals Inc MM-151 $ 244,479.24  
Merrimack Pharmaceuticals Inc MM-141 $ 244,479.24  
Merrimack Pharmaceuticals Inc MM-121 $ 244,479.24  
Merrimack Pharmaceuticals Inc MM-302 $ 244,479.24  
Merrimack Pharmaceuticals Inc MM-111 $ 244,479.24  
Merrimack Pharmaceuticals Inc. MM-POD2 $ 184,931.50 $ 59,547.74
Merrimack Pharmaceuticals, Inc MM-POD3 $ 86,698.50 $ 157,780.74
Merrimack Pharmaceuticals, Inc MM-131 $ 244,479.24  
Merrimack Pharmaceuticals, Inc. MM-POD1 $ 193,380.50 $ 51,098.74
Merrimack Pharmaceuticals, Inc. MM-398 $ 9,228.50 $ 235,250.74
Mersana Therapeutics Inc XMT-1001 $ 244,479.25  
Mersana Therapeutics Inc siRNA $ 244,479.25  
Mersana Therapeutics, Inc XMT-1107 $ 244,479.25  
Metamark Genetics Inc Development of function-based prognostic assays to optimize and personalize cancer care $ 244,479.24  
Microbiotix Preclinical development of antagonists of host immunity $ 9,586.88 $ 10,187.29
Microbiotix, Inc Preclinical development of bacterial replication inhibitors $ 244,479.24  
Microbiotix, Inc Preclinical Inhibitors of Botulinum Neurotoxin A $ 244,479.24  
Microbiotix, Inc Preclinical development of novel anti-biofilm coatings for implanted medical devices $ 15,526.04 $ 64,817.83
Microbiotix, Inc Preclinical development of novel broad-spectrum hemorrhagic fever virus inhibitors $ 118,957.83 $ 125,521.41
Microbiotix, Inc. Clinical development of MBX400: a novel inhibitor of human cytomegalovirus infection $ 244,479.24  
Microbiotix, Inc. Preclinical inhibitors of non-replication essential bacterial targets $ 244,479.24  
Microbiotix, Inc. Preclinical Inhibitors of bacterial virulence factors $ 160,378.98 $ 84,100.26
MicroCHIPS Inc Development of an implantable one year Continuous Glucose Monitoring System $ 244,479.25  
MicroCHIPS Inc Development of an implantable drug delivery device controlled release of PTH for one year $ 244,479.25  
MindChild Medical Inc Meridian Monitor $ 111,795.00 $ 132,684.24
MINERVA BIOTECHNOLOGIES CORP THERAPEUTIC DISABLES PRIMAL GROWTH MECHANISM ON CANCER STEM CELLS $ 244,479.24  
Mobius Imaging LLC SurgiTom $ 244,479.25  
Modular Genetics, Inc. Biosynthetic Meridamycin Analogs for Neurological Disorders $ 170,718.50 $ 73,760.75
MOLECULAR INSIGHT PHARMACEUTICALS INC ZEMIVA $ 244,479.25  
Molecular Insight Pharmaceuticals Inc Trofex $ 244,479.25  
MOLECULAR INSIGHT PHARMACEUTICALS INC SOLAZED $ 211,316.50 $ 33,162.75
Molecular Insight Pharmaceuticals, Inc Azedra - Neuroblastoma $ 244,479.25  
Molecular Insight Pharmaceuticals, Inc. Azendra - Pheochromocytoma $ 244,479.25  
Molecular Insight Pharmaceuticals, Inc. Onalta $ 244,479.25  
Momenta Pharmaceuticals, Inc M118, a novel antigoagulant to treat patients diagnosed with Acute Coronary $ 244,479.25  
Momenta Pharmaceuticals, Inc  Platform for Glycosaminoglycan Therapeutics-Novel Multimodal Drugs for Multifaceted diseases $ 244,479.25  
Momenta Pharmaceuticals, Inc M402- A novel multimodal inhibitor of tumor metastasis $ 244,479.25  
Momenta Pharmaceuticals, Inc Development of a biologics platform utilizing through characterization to ensure purity $ 244,479.25  
Nano Surfaces, Inc. Drug Delivery Micelles $ 244,479.25  
Nanobiosym Diagnostics Gene-RADAR for Medical Molecular Diagnostics $ 72,164.00 $ 172,315.24
Nanobiosym, Inc Single Molecule Drug Discovery $ 244,479.24  
NetBio, Inc Rapid Nucleic Acid-Based Diagnosis of STDs at the Point-of -Care $ 244,479.24  
NeurAxon (USA) Inc. NXN-462 for chronic daily headache and post-herpetic neuralgia $ 42,011.00 $ 202,468.24
NeurAxon (USA), Inc. NXN-188 for acute migraine $ 244,479.24  
NeuroHealing Pharmaceuticals, Inc. NH001 $ 180,467.50 $ 64,011.75
Neurometrix Inc Precision Targeted Therapeutic Delivery System for Peripheral Nerve Indications $ 244,479.24  
Neuron Systems, Inc Development of a definitive treatment for dry amd and stargardt's diesease $ 244,479.25  
NeuroPhage Pharmaceuticals, Inc. NPT001, a novel disease-modifying treatment for Alzheimer's Disease $ 244,479.25  
Neuroptix Corporation Ocular Diagnostic Test for Alzheimer's Disease $ 244,479.24  
Nextcea, Inc. Diagnosis and Therapy of Drug-Induced Phospholipidosis and of Niemann-Pick Diseases   $ 66, 107.24
Nikan Pharmaceuticals, LLC Development of Novel Compounds for Treatment of Inflammatory Disorders in Humans $ 6,333.50 $ 2,855.00
Nimbus Apollo, Inc. Preclinical R&D to advance lead molecules targeting ACC for obesity and diabetes   $ 196,019.50
Nimbus Discovery Inc R&D to advance programs targeting PFKFB3 and ZAP70 kinases for cancer & inflammation $ 71,412.50 $ 173,066.75
Nimbus Iris Inc Preclinical R&E to advance lead molecules targeting IRAK4 for inflammatory disease   $ 244,479.25
NinePoint Medical, Inc. N-lighten Optical Diagnostic and Therapeutic System   $ 244,479.25
NKT Therapeutics INC Development of Antibodies Directed Towards NKT Cells $ 244,479.24  
NormOxys, Inc Development of OXY111A for the Treatment of Cancer and Cardiovascular Disease $ 244,479.25  
Novelos Therapeutics, Inc. NOV-002 Development $ 244,479.25  
Nuclea Biotechnologies LLC Therapeutic Diagnostic/Prognostic Assay Development Program $ 244,479.25  
Nuclea Biotechnologies, LLC Research Methodology for Therapeutic/Diagnostic Discovery $ 228,990.00 $ 15,489.25
Nuclea Biotechnologies, LLC Humanized Anti-Cancer Monoclonal Antibodies $ 79,104.00 $ 165,375.25
Ocular Therapeutix, Inc Epi-Coat $ 132,373.00 $ 112,106.24
Ocular Therapeutix, Inc. ReSure Adherent Ocular Bandage $ 244,479.25  
Ocular Therapeutix, Inc. Punctum Drug Depot $ 244,479.25  
On-Q-ity Inc. Breast Biopsy Tumor Tissure test to predict response to anthracycline treatment $ 244,479.25  
On-Q-ity Inc. Lung Biomarker Tumor Tissue test to predict cisplatin response in lung cancer patients $ 200,422.50 $ 44,056.75
On-Q-ity Inc. HER-2 Circulating Tumor Cell test to inform therapeurtic choice for breast cancer patients $ 93,187.00 $ 151,292.25
On-Q-ity Inc. EGFR circulating tumor cell test to inform therapeutic choice for lung cancer patients $ 86,661.50 $ 157,817.75
OPK Biotech LLC HBOC-201/cGMP Manufacturing Facility   $ 244,479.25
ORA, Inc Novel Immunotherapy Treatment for Dry AMD $ 99,743.00 $ 144,736.25
ORA, Inc Novel Cerumenolytic $ 31,599.50 $ 18,486.00
ORA, Inc Novel Anti-Allergic $ 191,293.50 $ 53,185.75
ORA, Inc Novel Nasal Treatment for MRSA $ 90,844.50 $ 142,004.50
Orban Biotech LLC Insulin B Chain to Treat Type 1 Diabetes Mellitus   $ 244,479.25
Orbital Therapy, LLC Self-shielding radiotherapy device $ 244,479.24  
Ore Pharmaceutical Holdings Inc ORE1001 $ 244,479.25  
PAKA Pulmonary Pharmaceuticals Inc SP-B-Polymyxin Conjugate For Lung Infection   $ 34,230.00
Paloma Pharmaceuticals, Inc Palomid 529, a First -in-Class Dual TORC 1/2 Inhibitor of the P13k/Akt/m TOR Pathway $ 244,479.24  
Paratek Pharmaceuticals Inc Development of Oral Therapies for Major Chronic AutoImmune Diseases: MS, RA, IBD $ 244,479.25  
Paratek Pharmaceuticals, Inc Gram-Negative Hospital Bacterial Infections; Treatment and Prophylaxis $ 244,479.25  
Paratek Pharmaceuticals, Inc PTK 0796- A First-in-Class Oral & IV antiboiotic in Phase 3 for Serious Infections, incl. MRSA $ 244,479.25  
Pear Tree Pharmaceuticals, Inc Treatment of Moderate to Severe Vulvar and Vaginal Atrophy in Menopausal Patients $ 152,775.40 $ 91,703.85
Peptimmune, Inc. PI-2301 for thre ftreatment of Relapsing and Remitting Multiple Sclerosis (RRMS) $ 244,479.25  
Pervasis Therapeutics, Inc Development of PVS-10200 for Peripheral Artery Disease $ 244,479.25  
Pervasis Therapeutics, Inc. Development of Vascugel® to Sustain Arteriovenous Access for Hemodialysis $ 244,479.25  
Pervasis Therapeutics, Inc. Development of Tissue-Engineered Endothelial Cell Therapy for Brain and Prostate Cancer $ 30,307.90 $ 161,113.04
Pervasis Therapeutics, Inc. Devel. Of Tissue-Engineered Endothelial Cell Therapy to Supplement Orthopedic Procedures $ 35,022.33 $ 209,456.92
PGxHealth LLC Vilazodone: A novel treatment for major depressive disorder $ 244,479.25  
PGxHealth LLC Apadenoson: A novel pharmacologic stress agent for myocardial perfusion imaging $ 244,479.25  
Pharmalucence, Inc Lymph Node Localization by Tc-99m Sulfur Colloid Injection $ 85,732.00 $ 158,747.24
Phase Design Research CNS penetrating anti-inflammatory/metal chelators for treating neuroinflammation $ 29,921.79 $ 37,500.00
Physical Sciences Inc Continuous Automated Mandibular Distractor $ 71,626.00 $ 166,094.50
Physical Sciences Inc. Breath Test for Cancer Therapy $ 106,900.50 $ 137,578.75
Physical Sciences Inc. Dosimeters for Photodynamic Cancer Therapy (PDT) $ 242,635.00 $ 1,844.24
Physical Sciences Inc. Image-Guided Intervention for Pancreatic Cysts $ 128,383.00 $ 116,096.25
Physical Sciences, Inc Retinal Imaging for Disease Detection $ 244,479.24  
PLC Medical Systems Inc RenalGuard: A Novel Therapy to Prevent Contrast Induced Nephropathy $ 244,479.25  
Predictive Biosciences, Inc. Bladder Cancer Recurrence Monitoring Triage Test $ 244,479.25  
Predictive Biosciences, Inc. Test for Prognosis of Bladder Cancer $ 244,479.25  
Pressure BioSciences, Inc. Pressure Cycling Technology $ 244,479.25  
PrimeraDx, Inc. ViraQuant: Automated Quantitative Multi-Plex Viral Load Assay System $ 244,479.25  
Privo Technologies Insulin Chewing Gum   $ 4,000.00
Pro-Pharmaceuticals, Inc. Treatment and reversal of liver fibrosis using galectin blockers GRGs $ 10,083.67 $ 234,395.57
Pro-Pharmaceuticals, Inc. Anticancer treatments using galectin blockers combined with chemotherapies or biologics. $ 244,479.24  
Proteon Therapeutics, Inc. PRT-201 for Vascular Access in Chronic Hemodialysis Patients $ 244,479.24  
Provasculon, Inc Modified SDF-1 for the treatment of myocardial infarct and ischemic tissue $ 244,479.25  
Provenance Biopharmaceuticals Corp DI-Leu16-IL2 Anti-cancer Therapeutic $ 33,421.77 $ 211,057.48
Provenance Biopharmaceuticals Corp Veterinary immunocytokines to aid development of therapies for treatment of human cancers $ 29,117.77 $ 131,895.54
pSivida US Inc Sustained Release Brimonidine   $ 110,062.00
pSivida US, Inc. Antibodies for Treatment of Wet-Acute Macular Degeneration (Wet-AMD)   $ 98,087.00
Pulmatrix Inc. Inhaled Cationic Lining Modulators for Treatment and Prevention of Pulmonary Disease $ 244,479.25  
Pulsar Clinical Technologies Multiplex Microarray for Pre-Type 1 Diabetes Autoantibodies $ 65,183.30 $ 54,437.03
PureTech Ventures, LLC Inflammatory Bowel Disease (IBD) $ 76,490.76 $ 164,028.87
PureTech Ventures, LLC Autism $ 60,835.08 $ 86,590.68
PureTech Ventures, LLC Karuna $ 109,573.80 $ 134,905.45
Quanterix Corporation Development of the First Blood-based Diagnostic test for Alzheimer's Disease $ 244,479.24  
Quanterix Corporation A TNF-alpha Companion Diagnostic to Predict Response to Therapy in Crohn's Disease $ 127,716.00 $ 116,763.24
Quanterix Corporation Development of a Single Molecule Array Test for Prostate Cancer Recurrence Monitoring $ 244,479.24  
Radius Health Inc RAD1901 $ 244,479.25  
Radius Health Inc BA058 $ 244,479.25  
Radius Health, Inc SARM/RAD140 $ 244,479.25  
Rapid Micro Biosystems, Inc Enhanced Robustness of Rapid, Automated Microbial Enumeration $ 244,479.25  
Reflectance Medical Inc Non-Invasive Tissue Perfusion for Therapeutic Admin. $ 101,592.50 $ 142,886.74
Repligen Corporation RG3039-DcpS inhibitor for treatment of patients with Spinal Muscular Atrophy (SMA) $ 201,583.50 $ 42,895.75
Repligen Corporation RG2833, an inhibitor of HDAC-3 for the treatment of Friedreich's ataxia $ 244,479.25  
Repligen Corporation RG1068 - Synthetic Human Secretin for Pancreatic Imaging $ 244,479.24  
Resolvyx Pharmaceuticals Inc DEVELOPMENT OF RESOLVINS TO TREAT Chronic Inflammatory Disease $ 244,479.24  
RESOLVYX PHARMACEUTICALS, INC DEVELOPMENT OF RESOLVINS TO TREAT SIGHT-THREATENING DISEASE $ 244,479.24  
RFE Pharma Corp RFE-007 CAI injectable for treating diabetic retinopathy & age-related macular degeneration $ 38,561.00 $ 92,144.00
Rhythm Pharmaceuticals Inc Rm-493   $ 244,479.25
Rhythm Pharmaceuticals, Inc RM-131   $ 244,479.25
Rxi Pharmaceuticals Corporation Development of self-delivering RNA Interference (RNAi) therapeutic for the fibrotic disease $ 244,479.25  
Rxi Pharmaceuticals Corporation Oral Delivery of Glucose Encapsulated siRNAs for Rheumatoid Arthritis (RA) $ 244,479.25  
Rxi Pharmaceuticals Corporation Self-Delivering RNA Interference Therapeutic for Age-Related Macular Degeneration (AMD) $ 66,002.17 $ 178,477.08
Rxi Pharmaceuticals Corporation Self-Delivering RNA Interference Therapeutic for ALS (Lou Gehrig's Disease) $ 237,273.92 $ 7,205.33
Satori Pharmaceutcals Incorated Gamma-Secretase Modulators for the treatment of Alzheimer's Disease $ 244,479.24  
SBH Sciences Inc Development of a Therapy for Liver Fibrosis by Specific Targeting of Galectin-3 $ 98,932.50 $ 112,000.00
SBH Sciences, Inc Developing Therapy for Pancreatic Cancer Targeting Nuclear Export by CRM-1 $ 44,600.00 $ 140,100.00
Sci Dose LLC Ulcerative Colitis $ 188,828.00 $ 55,651.25
SciDose, LLC Docetaxel $ 244,479.25  
Seahorse Bioscience, Inc Prevention and treatment of age-related diseases by targeting defects in mitochondria. $ 244,479.25  
Seahorse Bioscience, Inc. Diagnosis of Metabolic and Age-Related Diseases $ 244,479.25  
Seaside Therapeutics Inc Development of Arbaclofen (STX209) for the Treatment of Fragile X Syndrome $ 244,479.25  
Seaside Therapeutics Inc, Development of Novel M1 Modulators for the Treatment of Austism and Fragil X syndrome   $ 244,479.25
Seaside Therapeutics Inc. Discovery Project to identify biomarkers related Austism Spectrum Disorders(ASD) $ 244,479.25  
Seaside Therapeutics, Inc. Development of mGluR5 Modulators for the Treatment of Autism and Fragile X Syndrome $ 244,479.25  
Seaside Therapeutics, Inc. Development of STX107 for the Treatment of Fragile X Syndrome $ 244,479.25  
Seaside Therapeutics, Inc. Development of Arbaclofen (STX209) for the Treatment of Autism Spectrum disorders (ASD) $ 244,479.25  
Selecta Biosciences, Inc Nicotine Vaccine for Smoking Cessation and Relapse Prevention $ 244,479.25  
Selecta Biosciences, Inc A synthetic Nanoparticle Vaccine Platform to induce a Cytolytic T-Cell Response $ 244,479.24  
Selecta Biosciences, Inc. Development of a Synthetic Nanoparticle Vaccine Platform to Induce Protective Antibodies $ 244,479.25  
SelectX Pharmaceuticals Inc SXP2554: A Novel Inhaled Antibiotic   $ 244,479.25
SelectX Pharmaceuticals, Inc. SXP2523: A Novel Antibiotic for Serious Gram-Negative Infections $ 244,479.25  
Semaco Inc. Targeting Telomere-Associated Werner Protein to Treat Hematologic Malignancy $ 156,500.00 $ 87,979.24
Semprus BioSciences Semprus PICC (Peripherally Inserted Central Catheter) $ 244,479.25  
Sentien Biotechnologies, Inc. Stem Cell Therapeutic Devices for Critical Care   $ 244,479.25
SetPoint Medical Corporation Immune System Regulator Therapy $ 244,479.25  
Seventh Sense Biosystems, Inc. On Vivo, A Fully Integrated Blood Collection and Diagnostic Test Device $ 244,479.24  
Shape Pharmaceuticals, Inc. SHP-141 for the treatment of Cutaneous T-Cell Lymphoma(CTCL) $ 244,479.25  
SimulConsult, Inc SimuConsult Diagnostic Decision Support Software $ 244,479.25  
SmartCells, Inc SmartInsulin-The First Glucose-regulated insulin for Treating Diabetes $ 244,479.24  
Soteira, Inc Soteira Shield Kyphoplasty System $ 244,479.25  
Speech Technology and Applied Research Corp Objective Acoustic Speech Analysis for Post Concussional Blast Effects $ 626.50 $ 15,329.50
Speech Technology and Applied Research Corp System for DBS Programming for Speech Functionality in Parkinson's Disease $ 146,055.50 $ 98,423.75
Spring Bank Pharmaceuticals, Inc SB 9000 $ 244,479.24  
Still River Systems, Inc. Proton Beam Radiotherapy System (PBRT) $ 244,479.25  
Strohl Medical Technologies Inc SEP-RAD Stroke Detection Device   $ 34,975.00
Stromedix, Inc. Development of STX-100 as a novel therapeutic for the treatment of fibrotic diseases $ 244,479.24  
Sunshine Medical LLC Interactive feeding system for the premature infant   $ 244,479.25
Surface Logix, Inc SLx-2119, a small molecule inhibitor of Rho kinase 2 (ROCK2) for oncology and fibrosis $ 244,479.24  
Surface Logix, Inc Intestinally selective small molecule activators of satiety $ 244,479.24  
Surface Logix, Inc SLx-2101, a small molecule PDES inhibitor targeting cardiovascular disease $ 244,479.24  
Surface Logix, Inc SLx-4090 Microsomal Triglyceride Transfer Protein (MTP) $ 244,479.24  
Surface Logix, Inc 50 Soldiers Field Place $ 244,479.24  
Surface Logix, Inc. Intestinally selective small molecule inhibitors of DGAT for obesity and diabetes $ 232,867.49 $ 11,611.75
Synageva BioPharma Corp Enhancement of the glycosylation machinery of the Synageva Expression Platform $ 16,995.76 $ 107,290.28
Synageva BioPharma Corp SBC-101 $ 244,479.25  
Synageva BioPharma Corp SBC-091 $ 244,479.24  
Synageva BioPharma Corp SBC-014 $ 244,479.24  
Synageva BioPharma Corp SBC-055 $ 244,479.24  
Synageva BioPharma Corp SBC-103 $ 24,026.32 $ 105,693.33
Synageva BioPharma Corp SBC-105   $ 91,706.28
Synageva BioPharma Corp. SBC-104   $ 244,479.25
Synageva BioPharma Corp. SBC-102 $ 244,479.24  
Synageva BioPharma Corp. SBC-201 $ 182,911.81 $ 55,148.08
Synageva BioPharma Corp. SBC-202 $ 89,388.76 $ 47,469.53
Synageva BioPharma Corp. PTR-302   $ 101,394.51
SynapDx Corporation Retrospective Study and Prospective Trial to Develop Autism Spectrum Disorder Diagnostic   $ 244,479.25
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Entinostat for the Treatment of Breast Cancer and HL $ 244,479.24  
SynDevRX, Inc High potency polymer/metAP2 inhibitors for the treatment of cancer $ 216,825.00 $ 27,654.24
Syndexa Pharmaceuticals Corp ISR Modulators as Novel Drugs for the Treatment of Type 2 Diabetes and Metabolic Diseases $ 244,479.24  
Syndexa Pharmaceuticals Corp. Novel Bivalent JNK Modulators for the Treatment of Obesity and Type 2 Diabetes $ 244,479.24  
Synovex Corporation SDP051 is a Cad-11 antagonist antibody for the treatment of rheumatoid arthritis $ 244,479.25  
Synta Pharmaceuticals Corp Development of elesclomol as a cancer therapeutic $ 244,479.24  
Synta Pharmaceuticals Corp Development of a novel, small molecule Hsp90 inhibitor, STA-9090, as a cancer therapeutic $ 244,479.24  
Synta Pharmaceuticals Corp. Oral CRAC channel inhibitor therapeutics for inflammatory diseases and cancer $ 244,479.25  
Synta Pharmaceuticals Corp. Oral Hsp90 inhibitor therapies for cancer, inflammatory and neurodegenerative diseases. $ 244,479.24  
T2 Biosystems, Inc Tacrolimus and Creatinine Project $ 244,479.25  
T2 Biosystems, Inc Dx Platform Project $ 244,479.25  
T2 Biosystems, Inc. Candida Project $ 244,479.25  
Taligen Therapeutics, Inc. TT30 therapeutic recombinant fusion protein to modulate Complement system $ 244,479.24  
Targeted Cell Therapies, LLC Development of a Novel Oral Delivery Technology or Large Molecule Therapeutics $ 73,440.50 $ 131,500.00
TARIS Biomedical Inc A novel drug-device combination prod. To improve the treatment of superficial bladder cancer $ 244,479.25  
Taris Biomedical, Inc LiRIS: A novel local therapy for the management of discomfort associated with ureteral stent $ 244,479.25  
TARIS Biomedical, Inc LiRIS: A novel drug-device combination product for the treatment of Interstitial Cystitis $ 244,479.25  
Temple Therapeutics, LLC New Therapies for Cancer using Mesenchymal Stem Cells (MSC's) expressing TRAIL   $ 244,479.25
Tepha Inc Hernia Mesh with Therapeutic Coating $ 244,479.24  
Tetraphase Pharmaceuticals Inc TP-834:A Promising New Oral Antibiotic for Community Acquired Pneumonia(CABP) $ 244,479.25  
Tetraphase Pharmaceuticals, Inc. TP-434: A Potent New Antibiotic To Treat a Broad Range of Multi-Drug Resistant "Superbugs"             834:A Promising New Oral Antibiotic for Community Acquired Pneumonia(CABP) $ 244,479.25  
Tetraphase Pharmaceuticals, Inc. TP-2758: A Novel and Exciting Oral Antibiotic for Complicated Urinary Tract Infections (cUTI) $ 244,479.25  
Theracrine Inc Monoclonal antibodies targeting cancer-specific osteopontin (vOPN)   $ 244,479.24
Theracrine, Inc Dual CXCR/1CXCR2 Inhibitor for the Treatment of Metastatic Cancer   $ 244,479.25
Theracrine, Inc Fascin inhibitor for the Treatment of metastatic Cancer   $ 244,479.24
Tokai Pharmaceuticals, Inc. TOK-001 $ 244,479.25  
Tolerx, Inc. Development of a Targeted Immunotherapeutic for the Treatment of Type 1 Diabetes. $ 244,479.24  
Tolerx, Inc. Development of Novel Anti-ILT Immunotherapeutics for the Treatment of Cancer $ 110,144.11 $ 134,335.13
Tolerx, Inc. Development of a Novel Anti-GITR Monoclonal Antibody as an Immunotherapy for Cancer. $ 244,479.24  
Tomophase Corporation Optical Coherence Tomographic Imaging System (OCTIS ™ ) $ 242,476.00 $ 2,003.24
Translational Therapeutics Inc. Cancer Therapeutics System $ 55,532.00 $ 188,947.25
U.S. Genomics Inc Highly Multiplexed Infectious Disease Diagnostics Based on Single Molecule DNA Analysis $ 244,479.25  
VANAS ONCOLOGY, INC BCP-21, A Novel Anti-Cancer Molecule $ 136,512.91 $ 107,966.33
Variation Biotechnologies (US), Inc c/o Variation Biotechnologies Inc Thermostable Vaccine   $ 244,479.25
Variation Biotechnologies (US), Inc, c/o Variation Biotechnologies Inc. Oral Shigella Vaccine   $ 244,479.25
Variation Biotechnologies (US), Inc. Variosite Technology $ 235,077.50 $ 9,401.75
Variation Biotechnologies (US), Inc. c/o Variation Biotechnologies Inc. Oral Vaccine $ 244,479.25  
VasoTech, Inc. A Novel Drug-Eluting Stent -- Power Stent ® -- for Coronary Arterial Disease Treatment $ 110,119.50 $ 134,359.75
Velico Medical, INC Refrigerated Platelets $ 7,500.00 $ 59,733.00
VELICO MEDICAL, INC. SPRAY DRIED PLASMA $ 244,479.25  
Verax Biomedical Incorporated PGD Platelet Test Device $ 244,479.24  
Veritas Health Solutions LLC Information Technology Management of Adolescent Depression (iTAD) $ 53,427.50 $ 11,455.50
Virdante Pharmaceuticals, Inc sFc-Recombinant Sialylated Immunoglobulin G (lgG) Fc fragments   $ 244,479.24
Virdante Pharmaceuticals, Inc Svig - Siaylated Intravenous Immunoglobulin $ 244,479.24  
Visterra, Inc (f/k/a Parasol Therapeutics, Inc PAR401: A Potent, Selective Anti-Influenza Therapeutic and Prophylactic $ 244,479.24  
ViThera LLC Development of an engineered bacterial therapy of Inflammatory Bowel Disease $ 5,739.16 $ 216,250.00
Vortex Medical Inc AngioVac $ 244,479.24  
Wadsworth Medical Technologies, Inc. Novel Device to Reduce Surgical Site Infection $ 71,683.00 $ 172,796.24
X-BODY, Inc XB-387, a PDGFRB Antibody Therapeutic for Non-Small Cell Lung Cancer $ 244,479.24  
Xcellerex Inc XRX-001 Inactivated Yellow Fever Vaccine $ 244,479.24  
Zafgen Inc T2D Program $ 244,479.25  
Zafgen, Inc. ZGN-440 $ 244,479.25  
ZIOPHARM Oncology, Inc. Indibulin $ 244,479.25  
ZIOPHARM Oncology, Inc. Palifosfamide $ 244,479.25  
ZIOPHARM Oncology, Inc. Darinaparsin $ 244,479.25  
Page Last Reviewed or Updated: 07-Apr-2014